Cargando…
Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic
OBJECTIVES: The COVID‐19 pandemic bears the risk of delayed cancer diagnoses. METHODS: Study on the diagnostic pathway of sinonasal malignancies during the COVID‐19 pandemic. RESULTS: Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartil...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513453/ https://www.ncbi.nlm.nih.gov/pubmed/34667832 http://dx.doi.org/10.1002/lio2.640 |
_version_ | 1784583216150085632 |
---|---|
author | Meerwein, Christian M. Stadler, Thomas M. Balermpas, Panagiotis Soyka, Michael B. Holzmann, David |
author_facet | Meerwein, Christian M. Stadler, Thomas M. Balermpas, Panagiotis Soyka, Michael B. Holzmann, David |
author_sort | Meerwein, Christian M. |
collection | PubMed |
description | OBJECTIVES: The COVID‐19 pandemic bears the risk of delayed cancer diagnoses. METHODS: Study on the diagnostic pathway of sinonasal malignancies during the COVID‐19 pandemic. RESULTS: Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartile range [IQR] 104‐193) vs 139 days (IQR 103‐219) (P = .60). Median time from first appointment at our institution to treatment initiation was even reduced in 2020: 18 days (IQR 11‐25) vs 11 days (IQR 7‐17) (P = .02). A trend toward advanced tumor stages during the pandemic was seen: 11/30 patients (36.7%) ≥ stage 4 in 2018 to 2019 vs 12/19 patients (63.2%) ≥ stage 4 in 2020 (P = .064). CONCLUSION: Both, time to diagnosis and time to treatment initiation were similar during the pandemic. However, a higher proportion of advanced tumors stages was observed. Despite the pandemic, we provided a swift diagnostic workflow, including a virtual tumor board decision and a prompt treatment initiation. Level of Evidence: 4. |
format | Online Article Text |
id | pubmed-8513453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85134532021-10-18 Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic Meerwein, Christian M. Stadler, Thomas M. Balermpas, Panagiotis Soyka, Michael B. Holzmann, David Laryngoscope Investig Otolaryngol Allergy, Rhinology, and Immunology OBJECTIVES: The COVID‐19 pandemic bears the risk of delayed cancer diagnoses. METHODS: Study on the diagnostic pathway of sinonasal malignancies during the COVID‐19 pandemic. RESULTS: Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartile range [IQR] 104‐193) vs 139 days (IQR 103‐219) (P = .60). Median time from first appointment at our institution to treatment initiation was even reduced in 2020: 18 days (IQR 11‐25) vs 11 days (IQR 7‐17) (P = .02). A trend toward advanced tumor stages during the pandemic was seen: 11/30 patients (36.7%) ≥ stage 4 in 2018 to 2019 vs 12/19 patients (63.2%) ≥ stage 4 in 2020 (P = .064). CONCLUSION: Both, time to diagnosis and time to treatment initiation were similar during the pandemic. However, a higher proportion of advanced tumors stages was observed. Despite the pandemic, we provided a swift diagnostic workflow, including a virtual tumor board decision and a prompt treatment initiation. Level of Evidence: 4. John Wiley & Sons, Inc. 2021-09-04 /pmc/articles/PMC8513453/ /pubmed/34667832 http://dx.doi.org/10.1002/lio2.640 Text en © 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Allergy, Rhinology, and Immunology Meerwein, Christian M. Stadler, Thomas M. Balermpas, Panagiotis Soyka, Michael B. Holzmann, David Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic |
title | Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic |
title_full | Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic |
title_fullStr | Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic |
title_full_unstemmed | Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic |
title_short | Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID‐19 pandemic |
title_sort | diagnostic pathway and stage migration of sinonasal malignancies in the era of the covid‐19 pandemic |
topic | Allergy, Rhinology, and Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513453/ https://www.ncbi.nlm.nih.gov/pubmed/34667832 http://dx.doi.org/10.1002/lio2.640 |
work_keys_str_mv | AT meerweinchristianm diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic AT stadlerthomasm diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic AT balermpaspanagiotis diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic AT soykamichaelb diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic AT holzmanndavid diagnosticpathwayandstagemigrationofsinonasalmalignanciesintheeraofthecovid19pandemic |